News

Filter

Current filters:

TecfideraBiotechnology

1 to 9 of 22 results

Forward Pharma sues Biogen Idec over Tecfidera sales in Germany

18-11-2014

Danish biopharmaceutical company Forward Pharma has filed a law suit against US biotech major Biogen…

Biogen IdecBiotechnologyForward PharmaGermanyLegalMarkets & MarketingNeurologicalTecfidera

Biogen Idec third-qtr net rockets 76% but shares slump

Biogen Idec third-qtr net rockets 76% but shares slump

23-10-2014

US biotech firm Biogen Idec saw its share price plunge 7% to $303.51, after its posted third-quarter…

Biogen IdecBiotechnologyFinancialNeurologicalTecfideraUSA

Strong and sustained efficacy reported for Tecfidera over five years

Strong and sustained efficacy reported for Tecfidera over five years

12-09-2014

Results from a five-year study with US biotech firm Biogen Idec’s Tecfidera show strong and sustained…

Biogen IdecBiotechnologyNeurologicalResearchTecfideraUSA

NICE recommends Biogen Idec’s Tecfidera for multiple sclerosis

NICE recommends Biogen Idec’s Tecfidera for multiple sclerosis

27-08-2014

The UK’s drugs watch dog, the National Institute for Health and Care Excellence (NICE), has recommended…

Biogen IdecBiotechnologyCNS DiseasesMultiple sclerosisRegulationTecfideraUK

IQWiG finds no added benefit for Biogen Idec’s Tecfidera

IQWiG finds no added benefit for Biogen Idec’s Tecfidera

08-08-2014

In its early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG)…

Biogen IdecBiotechnologyGermanyMSNeurologicalPricingRegulationTecfidera

Biogen Idec’s 2nd-qtr 40% revenues growth beats forecasts

Biogen Idec’s 2nd-qtr 40% revenues growth beats forecasts

23-07-2014

Shares of US biotech firm Biogen Idec jumped 7.35% to $326 in pre-market trading today, as the company…

AlprolixBiogen IdecBiotechnologyElocateFinancialImmunologyPharmacologyTecfideraUSA

NICE issues positive draft FAD guidance on Tecfidera

NICE issues positive draft FAD guidance on Tecfidera

11-07-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has issued…

Biogen IdecBiotechnologyMultiple sclerosisNeurologicalPricingRegulationTecfideraUK

Biogen Idec 1st-qtr 2014 revenue leaps 51%, driven by Tecfidera and MS franchise

23-04-2014

US biotech firm Biogen Idec first-quarter 2014 results today, including revenue of $2.1 billion, a 51%…

Biogen IdecBiotechnologyFinancialNeurologicalResearchTecfidera

1 to 9 of 22 results

COMPANY SPOTLIGHT

Menarini

Back to top